Nitin Bhasin, MD
Nephrology · San Dimas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 19 years
- Graduated 2007
Offices
3 locations · California Kidney Specialists · 16 clinicians in this group
Hospitals listed: Chino Valley Medical Center · City of Hope Helford Clinical Research Hospital · Emanate Health Foothill Presbyterian Hospital · Emanate Health Inter-Community Hospital · San Dimas Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhasin’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A109234 · Current
Licensed to practise in California · since 2009 · expires 2027-07-31 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Chino Valley Medical CenterChino, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.258, Oct 2024 – Sep 2025
- Emanate Health Foothill Presbyterian HospitalGlendora, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
- Emanate Health Inter-Community HospitalCovina, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
- San Dimas Community HospitalSan Dimas, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 56% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Chino Valley Medical Center
Behind the star rating — Deaths: 1 better, 2 the same, 0 worse of 3 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.258 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.1) · 201 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.6 · 38 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 966 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,420 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,449 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.27 (0.72 to 5.83) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.57 to 4) · 93 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.31 (0 to 1.27) · 921 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 40 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.7 · 167 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.3 · 71 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 53.4 · 160 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 296 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 43 cases | None | Jul 2023 – Jun 2025 |
What patients said (428 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 75% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Emanate Health Foothill Presbyterian Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2) · 475 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.74 to 1.58) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 64 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 1,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 2,452 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.57 (1.08 to 6.06) · 286 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.51 (0.83 to 4.19) · 283 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (1.35 to 20.62) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.86 (1.63 to 10.08) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.97 (0.06 to 1.88) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.662 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.026 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 44 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.2 · 139 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 308 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 520 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9 to 16.2) · 293 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 174 cases | No different | Jan 2024 – Dec 2024 |
What patients said (582 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 65% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Emanate Health Inter-Community Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.4 (0.39 to 2.4) · 990 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.53 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.56 (145.92 to 251.21) · 69 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.8 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 665 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 389 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 3,599 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 6,844 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.42) · 6,958 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (0.98 to 5.43) · 1,118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.46 (0 to 3.08) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (0.53 to 3.58) · 1,140 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.68 (1.69 to 15.67) · 450 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 397 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 0.97) · 5,698 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 213 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.578 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.853 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.438 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.205 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 352 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 631 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2 · 136 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 336 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.2 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 1,007 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.5 to 8) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (8.8 to 16.5) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.6) · 113 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 106 cases | No different | Jan 2024 – Dec 2024 |
What patients said (924 patients answered, 12% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for San Dimas Community Hospital
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 2 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.11) · 183 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.44 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 52 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 967 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 1,478 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.47) · 1,480 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.29 (0.72 to 5.85) · 115 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.57 to 4) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.15 (0 to 19.2) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (0.87 to 9.52) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.15) · 1,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 103 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.097 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17 · 41 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 40.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 377 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 44 cases | None | Jul 2023 – Jun 2025 |
What patients said (418 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 67% |
| Doctors "always" communicated well | 64% |
| Staff "always" explained | 51% |
| Yes, staff "did" give patients this information | 76% |
| Yes, staff "did" give patients information about help after discharge | 69% |
| Doctors "always" explained things so they could understand | 58% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 72% |
| Patients who gave a rating of "9" or "10" (high) | 50% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 63% |
| Nurses "always" listened carefully | 62% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 56% |
| Staff "always" explained possible side effects | 32% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$164,351
Medicare paid this office $164,351 for 547 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 382 | $88,631 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 148 | $18,148 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $15,261 | $101 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 32 | $9,766 | $94 |
| Return visit (30+ min) | 52 | $9,004 | $87 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 382 | $88,631 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 148 | $18,148 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $15,261 | $101 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 32 | $9,766 | $94 |
| Return visit (30+ min) | 52 | $9,004 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $6,203 | $148 |
| Critical care, first 30-74 minutes | 19 | $3,814 | $147 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 17 | $2,965 | $43 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 17 | $2,509 | $45 |
| New patient visit (45+ min) | 15 | $1,818 | $121 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,191 | $70 |
Who their Medicare patients are
547 Original Medicare patients in 2024. Average age 72 · Under 65 19% · 85 and older 15% · Women 46% · Also on Medicaid 68% · Health risk score 5.10. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 75% · Heart failure 63% · Coronary heart disease 56% · Atrial fibrillation 41% · COPD 36% · Depression 32% · Dementia 32% · Stroke 28% · Cancer 18%.
The office billed $401,710, Medicare allowed $207,050 and paid $164,351; for 2,116 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 547 | 2,116 | 72 | 5.10 | $401,710 | $164,351 |
| 2023 | 571 | 2,172 | 72 | 5.44 | $421,618 | $165,259 |
| 2022 | 539 | 2,502 | 72 | 5.08 | $455,688 | $163,758 |
| 2021 | 651 | 2,420 | 72 | 5.02 | $454,370 | $170,808 |
| 2020 | 621 | 2,464 | 72 | 5.51 | $473,378 | $174,244 |
| 2019 | 526 | 2,389 | 72 | 5.87 | $441,208 | $159,065 |
| 2018 | 612 | 2,693 | 71 | 5.82 | $490,891 | $177,495 |
| 2017 | 651 | 2,538 | 72 | 5.97 | $461,470 | $174,543 |
| 2016 | 628 | 2,235 | 73 | 5.00 | $313,665 | $164,524 |
| 2015 | 714 | 2,765 | 73 | 5.03 | $363,014 | $204,763 |
| 2014 | 185 | 625 | 73 | 4.49 | $84,460 | $47,203 |
| 2013 | 55 | 94 | 77 | 1.89 | $21,852 | $8,726 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 410 | $96,059 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 139 | $16,190 | $108 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 25 | $12,877 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $12,093 | $98 |
| Return visit (30+ min) | 48 | $9,195 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $6,722 | $137 |
| Hemodialysis procedure with physician evaluation | 37 | $2,860 | $60 |
| Critical care, first 30-74 minutes | 11 | $2,317 | $136 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,751 | $92 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,032 | $65 |
2022: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 416 | $99,712 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 120 | $14,934 | $113 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 28 | $11,500 | $78 |
| Return visit (30+ min) | 51 | $10,883 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,843 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $5,781 | $86 |
| Hemodialysis procedure with physician evaluation | 48 | $4,499 | $62 |
| Hospital discharge day management, more than 30 minutes | 29 | $3,042 | $89 |
| Critical care, first 30-74 minutes | 14 | $2,171 | $121 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,346 | $61 |
2021: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 498 | $99,616 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 142 | $16,997 | $114 |
| Return visit (30+ min) | 49 | $14,508 | $107 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 15 | $8,733 | $312 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 26 | $6,868 | $79 |
| Hemodialysis procedure with physician evaluation | 44 | $3,951 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,781 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,745 | $170 |
| Critical care, first 30-74 minutes | 14 | $2,728 | $152 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,468 | $92 |
2020: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 500 | $116,556 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 181 | $22,981 | $118 |
| Return visit (30+ min) | 45 | $8,671 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $5,825 | $91 |
| Hemodialysis procedure with physician evaluation | 50 | $4,266 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,321 | $175 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 11 | $2,415 | $80 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,606 | $94 |
| Hospital discharge day management, 30 minutes or less | 13 | $894 | $64 |
2019: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 401 | $106,709 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 149 | $20,099 | $116 |
| Return visit (30+ min) | 50 | $8,995 | $86 |
| Hemodialysis procedure with physician evaluation | 51 | $4,859 | $60 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 16 | $4,636 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $3,959 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,258 | $163 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,468 | $92 |
| Hospital discharge day management, 30 minutes or less | 12 | $876 | $63 |
2018: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 470 | $121,229 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 163 | $21,547 | $116 |
| Return visit (30+ min) | 48 | $7,794 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $4,675 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,311 | $166 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 15 | $3,546 | $79 |
| Hemodialysis procedure with physician evaluation | 32 | $3,113 | $61 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,847 | $92 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,436 | $62 |
| Short return visit (20+ min) | 18 | $956 | $46 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 491 | $116,635 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 209 | $27,446 | $115 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 29 | $5,417 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $4,729 | $84 |
| Return visit (30+ min) | 32 | $4,151 | $92 |
| Long return visit (40+ min) | 22 | $4,138 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,259 | $172 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,819 | $91 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,413 | $61 |
2016: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 416 | $86,507 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 166 | $20,759 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $16,468 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $15,438 | $88 |
| Hospital discharge day management, more than 30 minutes | 45 | $4,392 | $91 |
| Hospital discharge day management, 30 minutes or less | 56 | $3,691 | $61 |
| Return visit (30+ min) | 29 | $3,527 | $90 |
| Long return visit (40+ min) | 33 | $2,821 | $83 |
| Return visit (30+ min) | 31 | $2,056 | $59 |
| Long return visit (40+ min) | 11 | $1,872 | $117 |
| Critical care, first 30-74 minutes | 15 | $1,316 | $77 |
| Blood glucose (sugar) level | 13 | $79 | $5 |
2015: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 458 | $105,291 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $28,829 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $22,403 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 132 | $16,894 | $115 |
| Return visit (30+ min) | 39 | $4,105 | $89 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 16 | $3,620 | $77 |
| Long return visit (40+ min) | 21 | $3,114 | $120 |
| Return visit (30+ min) | 44 | $3,106 | $66 |
| Hospital discharge day management, more than 30 minutes | 32 | $3,092 | $91 |
| Long return visit (40+ min) | 28 | $2,627 | $94 |
| New patient visit (60+ min) | 17 | $2,292 | $135 |
| Critical care, first 30-74 minutes | 12 | $2,097 | $161 |
| Hospital discharge day management, 30 minutes or less | 33 | $2,050 | $60 |
| New patient visit (45+ min) | 13 | $1,713 | $132 |
| Short return visit (20+ min) | 23 | $1,424 | $59 |
| Blood glucose (sugar) level | 22 | $136 | $5 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 96 | $24,800 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 64 | $8,363 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,449 | $164 |
| Long return visit (40+ min) | 20 | $2,824 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,071 | $86 |
| Return visit (30+ min) | 14 | $1,287 | $92 |
| Blood glucose (sugar) level | 11 | $58 | $5 |
2013: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,003 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,376 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,674 | $105 |
Medicaid work
$27,947 in 2024
Medicaid paid $27,947 for 1,260 billed services this clinician did in 2024, up to 61 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,128 | $23,218 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 132 | $4,729 |
| 2024 | 1,260 | 2 | 61 | $27,947 |
| 2023 | 1,732 | 4 | 74 | $43,585 |
| 2022 | 1,263 | 3 | 65 | $33,628 |
| 2021 | 969 | 3 | 46 | $24,178 |
| 2020 | 1,121 | 3 | 52 | $26,261 |
| 2019 | 743 | 2 | 37 | $18,599 |
| 2018 | 1,051 | 2 | 40 | $16,224 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,520 | $34,215 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 126 | $7,000 |
| Return visit (30+ min) | 66 | $1,907 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 20 | $464 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,131 | $26,497 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 92 | $6,271 |
| Return visit (30+ min) | 40 | $859 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 944 | $22,282 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 13 | $1,465 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 12 | $431 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,054 | $23,323 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 51 | $2,441 |
| Return visit (30+ min) | 16 | $497 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 729 | $17,757 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 14 | $842 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,021 | $14,887 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 30 | $1,337 |
Drugs they prescribed that Part D paid
$215,278
Pharmacies billed $215,278 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (23 of 876) in 2024. A higher opioid share than 9 in 10 peers; the typical nephrology clinician is at 0%.
708 generic and 155 brand-name prescriptions · $215,278 in drug cost · 73 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 45 | $31,280 | $695 |
| Velphoro | 11 | $16,995 | $1,545 |
| Ampicillin-Sulbactam | 18 | $1,485 | $83 |
| Labetalol | 15 | $1,388 | $93 |
| Insulin Lispro Kwikpen U-100 | 11 | $999 | $91 |
See all 26 drugs
| Farxiga | 45 | $31,280 | $695 |
| Velphoro | 11 | $16,995 | $1,545 |
| Ampicillin-Sulbactam | 18 | $1,485 | $83 |
| Labetalol | 15 | $1,388 | $93 |
| Insulin Lispro Kwikpen U-100 | 11 | $999 | $91 |
| Nano 2nd Gen Pen Needle | 13 | $964 | $74 |
| Nifedipine Er | 21 | $443 | $21 |
| Furosemide | 74 | $278 | $4 |
| Calcitriol | 20 | $227 | $11 |
| Donepezil | 13 | $172 | $13 |
| Lisinopril | 25 | $163 | $7 |
| Allopurinol | 16 | $147 | $9 |
| Clopidogrel | 16 | $145 | $9 |
| Simvastatin | 17 | $121 | $7 |
| Ropinirole | 13 | $109 | $8 |
| Losartan | 14 | $92 | $7 |
| Gabapentin | 18 | $86 | $5 |
| Carvedilol | 19 | $66 | $3 |
| Benazepril | 11 | $57 | $5 |
| Tramadol | 12 | $49 | $4 |
| Ciprofloxacin | 11 | $39 | $4 |
| Cephalexin | 20 | $38 | $2 |
| Amlodipine Besylate | 41 | $36 | $1 |
| Minoxidil | 11 | $32 | $3 |
| Glipizide | 16 | $29 | $2 |
| Metoprolol | 12 | $24 | $2 |
Year by year
| 2024 | 876 | 164 | 3% (23) | 18% | $215,278 |
| 2023 | 633 | 154 | 3% (20) | None | $118,863 |
| 2022 | 687 | 126 | 3% (20) | None | $87,636 |
| 2021 | 647 | 115 | 3% (22) | None | $77,060 |
| 2020 | 633 | 133 | 5% (30) | None | $101,645 |
| 2019 | 908 | 183 | 4% (33) | 15% | $94,898 |
| 2018 | 924 | 197 | 3% (30) | 14% | $81,362 |
| 2017 | 789 | 164 | 7% (55) | None | $54,523 |
| 2016 | 484 | 134 | 5% (22) | None | $38,365 |
| 2015 | 481 | 168 | 14% (66) | None | $37,397 |
| 2014 | 300 | 106 | 10% (30) | 20% | $26,932 |
| 2013 | 210 | 71 | 8% (16) | 20% | $36,166 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Velphoro | 12 | $20,510 | $1,709 |
| Farxiga | 20 | $15,089 | $754 |
| Levemir Flexpen | 15 | $9,540 | $636 |
| Vascepa | 11 | $1,088 | $99 |
| Nifedipine Er | 14 | $910 | $65 |
| Losartan | 25 | $415 | $17 |
| Tamsulosin | 17 | $341 | $20 |
| Gabapentin | 11 | $338 | $31 |
| Simvastatin | 21 | $317 | $15 |
| Nitrofurantoin Mono-Macro | 14 | $258 | $18 |
| Allopurinol | 17 | $193 | $11 |
| Amlodipine Besylate | 28 | $187 | $7 |
| Furosemide | 26 | $180 | $7 |
| Potassium Chloride | 11 | $177 | $16 |
| Ibuprofen | 14 | $141 | $10 |
| Minoxidil | 11 | $86 | $8 |
| Tramadol | 11 | $74 | $7 |
| Ciprofloxacin | 11 | $65 | $6 |
2022: 20 drugs
| Velphoro | 15 | $24,279 | $1,619 |
| Jardiance | 16 | $10,652 | $666 |
| Levemir Flextouch | 17 | $8,493 | $500 |
| Nifedipine Er | 23 | $1,041 | $45 |
| Metolazone | 16 | $722 | $45 |
| Potassium Citrate Er | 12 | $531 | $44 |
| Lactulose | 23 | $508 | $22 |
| Hydralazine | 14 | $403 | $29 |
| Tamsulosin | 13 | $378 | $29 |
| Losartan | 23 | $321 | $14 |
| Simvastatin | 27 | $273 | $10 |
| Carvedilol | 35 | $235 | $7 |
| Allopurinol | 14 | $227 | $16 |
| Furosemide | 45 | $208 | $5 |
| Amlodipine Besylate | 25 | $187 | $7 |
| Spironolactone | 18 | $96 | $5 |
| Minoxidil | 11 | $88 | $8 |
| Famotidine | 15 | $85 | $6 |
| Lisinopril | 11 | $73 | $7 |
| Glipizide | 17 | $41 | $2 |
2021: 17 drugs
| Velphoro | 11 | $16,968 | $1,543 |
| Nifedipine Er | 11 | $869 | $79 |
| Oxybutynin Chloride | 22 | $848 | $39 |
| Hydralazine | 19 | $390 | $21 |
| Losartan | 32 | $364 | $11 |
| Furosemide | 57 | $245 | $4 |
| Omeprazole | 12 | $230 | $19 |
| Nitrofurantoin Mono-Macro | 11 | $209 | $19 |
| Amlodipine Besylate | 40 | $204 | $5 |
| Alprazolam | 15 | $189 | $13 |
| Simvastatin | 26 | $140 | $5 |
| Allopurinol | 11 | $135 | $12 |
| Lisinopril | 14 | $74 | $5 |
| Ciprofloxacin | 12 | $56 | $5 |
| Tramadol | 15 | $54 | $4 |
| Ibuprofen | 13 | $49 | $4 |
| Spironolactone | 11 | $28 | $3 |
2020: 21 drugs
| Velphoro | 30 | $58,573 | $1,952 |
| Sevelamer Carbonate | 11 | $2,567 | $233 |
| Calcium Acetate | 19 | $1,069 | $56 |
| Omeprazole-Sodium Bicarbonate | 12 | $1,050 | $88 |
| Midodrine | 14 | $964 | $69 |
| Fluocinonide | 11 | $460 | $42 |
| Oxybutynin Chloride | 11 | $278 | $25 |
| Pantoprazole | 17 | $232 | $14 |
| Losartan | 19 | $193 | $10 |
| Omeprazole | 13 | $164 | $13 |
| Furosemide | 47 | $157 | $3 |
| Hydrocodone-Acetaminophen | 11 | $139 | $13 |
| Zolpidem | 17 | $136 | $8 |
| Amlodipine Besylate | 19 | $130 | $7 |
| Alprazolam | 20 | $122 | $6 |
| Atorvastatin | 11 | $102 | $9 |
| Rosuvastatin | 12 | $74 | $6 |
| Tramadol | 18 | $71 | $4 |
| Simvastatin | 14 | $58 | $4 |
| Gemfibrozil | 11 | $57 | $5 |
| Glipizide | 15 | $56 | $4 |
2019: 25 drugs
| Velphoro | 23 | $38,729 | $1,684 |
| Sevelamer Carbonate | 19 | $5,375 | $283 |
| Calcium Acetate | 17 | $1,182 | $70 |
| Omeprazole-Sodium Bicarbonate | 11 | $951 | $86 |
| Rosuvastatin | 13 | $891 | $69 |
| Midodrine | 18 | $423 | $24 |
| Nifedipine Er | 19 | $356 | $19 |
| Furosemide | 79 | $312 | $4 |
| Lisinopril | 46 | $280 | $6 |
| Zolpidem | 21 | $255 | $12 |
| Diphenoxylate-Atropine | 12 | $246 | $20 |
| Hydralazine | 15 | $244 | $16 |
| Amlodipine Besylate | 31 | $237 | $8 |
| Hydrocodone-Acetaminophen | 14 | $207 | $15 |
| Atorvastatin | 22 | $202 | $9 |
| Carvedilol | 15 | $186 | $12 |
| Omeprazole | 12 | $185 | $15 |
| Azithromycin | 28 | $176 | $6 |
| Alprazolam | 22 | $174 | $8 |
| Simvastatin | 27 | $147 | $5 |
| Pantoprazole | 13 | $145 | $11 |
| Gabapentin | 11 | $107 | $10 |
| Lorazepam | 16 | $67 | $4 |
| Tramadol | 14 | $54 | $4 |
| Glipizide | 14 | $28 | $2 |
2018: 25 drugs
| Renvela | 14 | $23,186 | $1,656 |
| Sevelamer Carbonate | 13 | $8,617 | $663 |
| Esomeprazole Magnesium | 14 | $1,292 | $92 |
| Nifedipine Er | 39 | $1,239 | $32 |
| Calcium Acetate | 16 | $1,200 | $75 |
| Rosuvastatin | 17 | $1,004 | $59 |
| Hydrocodone-Acetaminophen | 20 | $406 | $20 |
| Minoxidil | 22 | $380 | $17 |
| Levothyroxine | 22 | $371 | $17 |
| Losartan | 31 | $349 | $11 |
| Furosemide | 74 | $274 | $4 |
| Amlodipine Besylate | 17 | $254 | $15 |
| Atorvastatin | 22 | $219 | $10 |
| Azithromycin | 33 | $210 | $6 |
| Carvedilol | 22 | $166 | $8 |
| Lisinopril | 33 | $150 | $5 |
| Omeprazole | 16 | $147 | $9 |
| Paroxetine | 15 | $113 | $8 |
| Alprazolam | 21 | $90 | $4 |
| Simvastatin | 32 | $86 | $3 |
| Trazodone | 19 | $82 | $4 |
| Lovastatin | 13 | $80 | $6 |
| Benazepril | 14 | $69 | $5 |
| Lorazepam | 16 | $53 | $3 |
| Glipizide | 14 | $32 | $2 |
2017: 27 drugs
| Calcium Acetate | 25 | $2,710 | $108 |
| Esomeprazole Magnesium | 16 | $1,603 | $100 |
| Nifedipine Er | 40 | $1,201 | $30 |
| Hydrocodone-Acetaminophen | 41 | $703 | $17 |
| Metoprolol | 12 | $411 | $34 |
| Temazepam | 17 | $292 | $17 |
| Minoxidil | 16 | $246 | $15 |
| Lisinopril | 28 | $188 | $7 |
| Furosemide | 39 | $156 | $4 |
| Alprazolam | 21 | $148 | $7 |
| Rosuvastatin | 11 | $140 | $13 |
| Azithromycin | 21 | $130 | $6 |
| Spironolactone | 22 | $127 | $6 |
| Pantoprazole | 11 | $124 | $11 |
| Amlodipine Besylate | 23 | $109 | $5 |
| Clonidine | 19 | $107 | $6 |
| Pioglitazone | 11 | $97 | $9 |
| Ranitidine | 16 | $91 | $6 |
| Ciprofloxacin | 14 | $90 | $6 |
| Carvedilol | 17 | $84 | $5 |
| Ibu | 13 | $80 | $6 |
| Zolpidem | 14 | $75 | $5 |
| Simvastatin | 19 | $70 | $4 |
| Metoprolol | 15 | $63 | $4 |
| Lovastatin | 11 | $60 | $5 |
| Metformin | 12 | $54 | $5 |
| Gabapentin | 16 | $51 | $3 |
2016: 14 drugs
| Renvela | 14 | $15,405 | $1,100 |
| Januvia | 17 | $6,314 | $371 |
| Calcium Acetate | 36 | $3,517 | $98 |
| Hydrocodone-Acetaminophen | 17 | $364 | $21 |
| Metoprolol | 11 | $326 | $30 |
| Gabapentin | 22 | $199 | $9 |
| Amlodipine Besylate | 58 | $192 | $3 |
| Losartan | 13 | $189 | $15 |
| Levofloxacin | 11 | $168 | $15 |
| Spironolactone | 22 | $138 | $6 |
| Furosemide | 31 | $122 | $4 |
| Pioglitazone | 13 | $122 | $9 |
| Ciprofloxacin | 13 | $95 | $7 |
| Metformin | 11 | $51 | $5 |
2015: 13 drugs
| Renvela | 13 | $17,028 | $1,310 |
| Januvia | 16 | $5,791 | $362 |
| Prosol | 37 | $2,714 | $73 |
| Calcium Acetate | 17 | $1,610 | $95 |
| Hydrocodone-Acetaminophen | 35 | $860 | $25 |
| Losartan | 25 | $248 | $10 |
| Amlodipine Besylate | 40 | $172 | $4 |
| Lisinopril | 23 | $129 | $6 |
| Gabapentin | 12 | $100 | $8 |
| Azithromycin | 13 | $95 | $7 |
| Furosemide | 23 | $84 | $4 |
| Tramadol | 18 | $72 | $4 |
| Cephalexin | 14 | $67 | $5 |
2014: 7 drugs
| Renvela | 18 | $15,498 | $861 |
| Clinisol | 21 | $1,576 | $75 |
| Prosol | 12 | $798 | $67 |
| Furosemide | 14 | $424 | $30 |
| Atorvastatin | 12 | $370 | $31 |
| Hydrocodone-Acetaminophen | 16 | $217 | $14 |
| Lisinopril | 18 | $162 | $9 |
2013: 3 drugs
| Renvela | 13 | $13,231 | $1,018 |
| Lisinopril | 14 | $158 | $11 |
| Metformin | 11 | $100 | $9 |
Money from drug and device companies
$838 in 2025
| 2025 | 11 | 32 | None | $838 |
| 2024 | 16 | 42 | None | $2,141 |
| 2023 | 12 | 42 | None | $692 |
| 2022 | 15 | 36 | None | $948 |
| 2021 | 14 | 43 | None | $796 |
| 2020 | 7 | 25 | None | $475 |
| 2019 | 13 | 50 | None | $994 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Akebia Therapeutics | Vafseo | $266 | 10 payments
|
| Calliditas Therapeutics US | Tarpeyo | $213 | 8 payments
|
| Otsuka America Pharmaceutical | Jynarque | $125 | 4 payments
|
| Novo Nordisk | Rybelsus | $59 | 3 payments
|
| Travere Therapeutics | None | $35 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $33 | 1 payment
|
See all 32 published payments
| Calliditas Therapeutics US | Meals · 2025-12-18 | Tarpeyo | $39 |
| Akebia Therapeutics | Meals · 2025-12-18 | Vafseo | $17 |
| Akebia Therapeutics | Meals · 2025-12-08 | Vafseo | $127 |
| Otsuka America Pharmaceutical | Meals · 2025-12-02 | Jynarque | $33 |
| Calliditas Therapeutics US | Meals · 2025-11-26 | Tarpeyo | $21 |
| Travere Therapeutics | Meals · 2025-10-29 | None | $35 |
| Novo Nordisk | Meals · 2025-10-15 | Rybelsus | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-10-03 | Jynarque | $33 |
| Akebia Therapeutics | Meals · 2025-10-03 | Vafseo | $6 |
| Novo Nordisk | Meals · 2025-09-29 | Rybelsus | $18 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Fabhalta | $19 |
| Akebia Therapeutics | Meals · 2025-09-26 | Vafseo | $8 |
| CorMedix | Meals · 2025-09-24 | None | $30 |
| Akebia Therapeutics | Meals · 2025-09-11 | Vafseo | $18 |
| Alexion Pharmaceuticals | Meals · 2025-08-26 | Ultomiris | $33 |
| Akebia Therapeutics | Meals · 2025-08-07 | Vafseo | $23 |
| Calliditas Therapeutics US | Meals · 2025-08-04 | Tarpeyo | $39 |
| Calliditas Therapeutics US | Meals · 2025-07-29 | Tarpeyo | $31 |
| Akebia Therapeutics | Meals · 2025-07-18 | Vafseo | $7 |
| Akebia Therapeutics | Meals · 2025-07-09 | Vafseo | $7 |
| Otsuka America Pharmaceutical | Meals · 2025-07-08 | Jynarque | $33 |
| Mallinckrodt Hospital Products | Meals · 2025-06-03 | Acthar | $22 |
| Amgen | Meals · 2025-05-20 | Krystexxa | $16 |
| Calliditas Therapeutics US | Meals · 2025-04-28 | Tarpeyo | $28 |
| Calliditas Therapeutics US | Meals · 2025-04-10 | Tarpeyo | $23 |
| Novo Nordisk | Meals · 2025-03-04 | Ozempic | $18 |
| Calliditas Therapeutics US | Meals · 2025-02-25 | Tarpeyo | $17 |
| Calliditas Therapeutics US | Meals · 2025-02-25 | Tarpeyo | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-02-03 | Jynarque | $27 |
| Fresenius USA Marketing | Meals · 2025-01-28 | Velphoro | $20 |
| Akebia Therapeutics | Meals · 2025-01-14 | Vafseo | $27 |
| Akebia Therapeutics | Meals · 2025-01-09 | Vafseo | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,141
| Bayer Healthcare Pharmaceuticals | Kerendia | $1,382 | 11 payments
|
| Amgen | Aranesp | $88 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $74 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $73 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $65 | 2 payments
|
| Novo Nordisk | Ozempic | $64 | 3 payments
|
| Akebia Therapeutics | Auryxia | $63 | 3 payments
|
| GlaxoSmithKline | Benlysta | $61 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $52 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $50 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $42 | 2 payments
|
| Gilead Sciences | None | $32 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $32 | 1 payment
|
| CorMedix | Defencath | $25 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $22 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $15 | 1 payment
|
2023: $692
| AstraZeneca Pharmaceuticals LP | Farxiga | $214 | 7 payments
|
| Akebia Therapeutics | Auryxia | $96 | 5 payments
|
| GlaxoSmithKline | Benlysta | $91 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $63 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $60 | 3 payments
|
| Travere Therapeutics | None | $41 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $28 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $27 | 1 payment
|
| Vifor Pharma | Veltassa | $20 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $18 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $18 | 1 payment
|
| Fresenius USA Marketing | 2008t Bluestar Hemodialysis Machine | $17 | 1 payment
|
2022: $948
| AstraZeneca Pharmaceuticals LP | Lokelma | $231 | 9 payments
|
| Aurinia Pharma U.S. | Lupkynis | $125 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $117 | 5 payments
|
| Amgen | Parsabiv | $96 | 4 payments
|
| Novartis Pharmaceuticals | None | $93 | 2 payments
|
| GlaxoSmithKline | Benlysta | $63 | 3 payments
|
| Akebia Therapeutics | Auryxia | $54 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $44 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $25 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $23 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $18 | 1 payment
|
| CSL Behring | None | $17 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $16 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $15 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $13 | 1 payment
|
2021: $796
| AstraZeneca Pharmaceuticals LP | Farxiga | $235 | 10 payments
|
| Amgen | Parsabiv | $113 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $95 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $86 | 3 payments
|
| Akebia Therapeutics | Auryxia | $42 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $40 | 2 payments
|
| Vifor Pharma | Veltassa | $34 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $29 | 2 payments
|
| Boston Scientific | Watchman | $26 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $25 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $23 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $21 | 1 payment
|
| GlaxoSmithKline | Benlysta | $14 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $14 | 1 payment
|
2020: $475
| AstraZeneca Pharmaceuticals LP | Lokelma | $112 | 6 payments
|
| Otsuka America Pharmaceutical | Jynarque | $85 | 4 payments
|
| Horizon Therapeutics plc | Krystexxa | $75 | 4 payments
|
| Akebia Therapeutics | Auryxia | $69 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $68 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $48 | 3 payments
|
| Ultragenyx Pharmaceutical | None | $19 | 1 payment
|
2019: $994
| Otsuka America Pharmaceutical | Jynarque | $237 | 13 payments
|
| Relypsa | Veltassa | $167 | 5 payments
|
| Amgen | Parsabiv | $151 | 6 payments
|
| Mallinckrodt Enterprises | Acthar | $122 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $118 | 8 payments
|
| Akebia Therapeutics | Auryxia | $47 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $37 | 2 payments
|
| Genzyme | Fabrazyme | $22 | 1 payment
|
| Alexion Pharmaceuticals | None | $22 | 1 payment
|
| Retrophin | (815) Thiola | $19 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $16 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $16 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| CSL Behring · A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study To Investigate the Efficacy and Safety of Csl300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis · 2025 | Their institution | $435,676 |
| Bayer HealthCare Pharmaceuticals Inc. · Osocimab in Esrd Phase 2b Study · 2021 | Their institution | $255,068 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Dose Finding Pocc in Ckd · 2022 | Their institution | $70,205 |
| CSL Behring · A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study To Investigate the Efficacy and Safety of Csl300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis · 2024 | Their institution | $49,110 |
| AstraZeneca Pharmaceuticals LP · A Phase I and Iia Randomized,Double Blind,Placebo Controlled Study To Evaluate the Safety and Pharmacokinetics of Azd7760 in Healthy Participants and in Patients With End Stage Kidney Disease Receiving Hemodialysis Through A Central Venous Catheter · 2025 | Their institution | $40,941 |
| Bayer HealthCare Pharmaceuticals Inc. · Osocimab in Esrd Phase 2b Study · 2020 | Their institution | $36,377 |
| Merck Sharp & Dohme Corporation · A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of Mk-2060 in Participants With End Stage Renal Disease Receiving Hemodialysis. · 2021 | Their institution | $34,076 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Dose Finding/Pocc in Ckd · 2024 | Their institution | $26,735 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Dose Finding Pocc in Ckd · 2023 | Their institution | $21,226 |
| Boehringer Ingelheim International GmbH · Phase II Dose Finding Pocc in Ckd · 2022 | Their institution | $26 |
Professional record
- NPI
- 1669790838
- Licence
- CA A109234California A109234: Current · expires 2027-07-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 1335 Cypress Street,, Suite 205, San Dimas, CA, 91773
- NPI first listed
- 2010-05-12
- NPI last updated
- 2020-08-28
- NPI record certified
- 2020-08-28
This is when the NPI record was last certified, not a medical board exam.